FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2548144489> ?p ?o ?g. }

• W2548144489 endingPage "83222" @default.
• W2548144489 startingPage "83208" @default.
• W2548144489 abstract "// Su-Fern Tan 1 , Xin Liu 2 , Todd E. Fox 3 , Brian M. Barth 4 , Arati Sharma 2 , Stephen D. Turner 5 , Andy Awwad 2 , Alden Dewey 2 , Kenichiro Doi 6 , Barbara Spitzer 7 , Mithun Vinod Shah 8 , Samy A.F. Morad 9, 10 , Dhimant Desai 11 , Shantu Amin 11 , Junjia Zhu 2 , Jason Liao 2 , Jong Yun 2, 11 , Mark Kester 3 , David F. Claxton 2 , Hong-Gang Wang 2, 12 , Myles C. Cabot 9 , Edward H. Schuchman 13 , Ross L. Levine 7 , David J. Feith 1, 14 , Thomas P. Loughran, Jr 1, 14 1 Department of Medicine, University of Virginia, Charlottesville, VA, USA 2 Penn State Hershey Cancer Institute, Hershey, PA, USA 3 Department of Pharmacology, University of Virginia, Charlottesville, VA, USA 4 Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, USA 5 Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA 6 Department of Pathology, Osaka City University Medical School, Osaka, Japan 7 Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA 8 Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA 9 Department of Biochemistry and Molecular Biology, East Carolina University, Brody School of Medicine, Greenville, NC, USA 10 Department of Pharmacology, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt 11 Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA 12 Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA 13 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mt. Sinai, New York, USA 14 University of Virginia Cancer Center, Charlottesville, VA, USA Correspondence to: Thomas P. Loughran, Jr, email: tploughran@virginia.edu Keywords: acid ceramidase, myeloid cell leukemia sequence 1 protein, ceramide, sphingosine 1-phosphate, leukemia Received: May 20, 2016     Accepted: October 13, 2016     Published: November 4, 2016 ABSTRACT There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promotes cancer cell growth and survival. Acid ceramidase (AC) catalyzes ceramide breakdown to sphingosine, the precursor for S1P. We report for the first time that AC is required for AML blast survival. Transcriptome analysis and enzymatic assay show that primary AML cells have high levels of AC expression and activity. Treatment of patient samples and cell lines with AC inhibitor LCL204 reduced viability and induced apoptosis. AC overexpression increased the expression of anti-apoptotic Mcl-1, significantly increased S1P and decreased ceramide. Conversely, LCL204 induced ceramide accumulation and decreased Mcl-1 through post-translational mechanisms. LCL204 treatment significantly increased overall survival of C57BL/6 mice engrafted with leukemic C1498 cells and significantly decreased leukemic burden in NSG mice engrafted with primary human AML cells. Collectively, these studies demonstrate that AC plays a critical role in AML survival through regulation of both sphingolipid levels and Mcl-1. We propose that AC warrants further exploration as a novel therapeutic target in AML." @default.
• W2548144489 created "2016-11-11" @default.
• W2548144489 creator A5003440754 @default.
• W2548144489 creator A5004302802 @default.
• W2548144489 creator A5009075816 @default.
• W2548144489 creator A5020872528 @default.
• W2548144489 creator A5021687717 @default.
• W2548144489 creator A5025430347 @default.
• W2548144489 creator A5025660159 @default.
• W2548144489 creator A5026502757 @default.
• W2548144489 creator A5031335801 @default.
• W2548144489 creator A5031949915 @default.
• W2548144489 creator A5032107158 @default.
• W2548144489 creator A5033462957 @default.
• W2548144489 creator A5033593866 @default.
• W2548144489 creator A5034341624 @default.
• W2548144489 creator A5039672451 @default.
• W2548144489 creator A5040990076 @default.
• W2548144489 creator A5043754907 @default.
• W2548144489 creator A5048058203 @default.
• W2548144489 creator A5056115129 @default.
• W2548144489 creator A5058544614 @default.
• W2548144489 creator A5059706312 @default.
• W2548144489 creator A5068228499 @default.
• W2548144489 creator A5075451106 @default.
• W2548144489 creator A5082424937 @default.
• W2548144489 date "2016-11-04" @default.
• W2548144489 modified "2023-10-16" @default.
• W2548144489 title "Acid ceramidase is upregulated in AML and represents a novel therapeutic target" @default.
• W2548144489 cites W1492609361 @default.
• W2548144489 cites W1516934351 @default.
• W2548144489 cites W1976981476 @default.
• W2548144489 cites W1977644244 @default.
• W2548144489 cites W1980792888 @default.
• W2548144489 cites W1983347881 @default.
• W2548144489 cites W2006468304 @default.
• W2548144489 cites W2007222184 @default.
• W2548144489 cites W2009977888 @default.
• W2548144489 cites W2022609820 @default.
• W2548144489 cites W2026064268 @default.
• W2548144489 cites W2027027613 @default.
• W2548144489 cites W2028956758 @default.
• W2548144489 cites W2035191293 @default.
• W2548144489 cites W2037173694 @default.
• W2548144489 cites W2037753361 @default.
• W2548144489 cites W2040331428 @default.
• W2548144489 cites W2047590682 @default.
• W2548144489 cites W2047607345 @default.
• W2548144489 cites W2052250480 @default.
• W2548144489 cites W2059416155 @default.
• W2548144489 cites W2061690334 @default.
• W2548144489 cites W2066640259 @default.
• W2548144489 cites W2067437043 @default.
• W2548144489 cites W2068444709 @default.
• W2548144489 cites W2069412624 @default.
• W2548144489 cites W2071523891 @default.
• W2548144489 cites W2082306016 @default.
• W2548144489 cites W2083315334 @default.
• W2548144489 cites W2102423175 @default.
• W2548144489 cites W2102461774 @default.
• W2548144489 cites W2107916120 @default.
• W2548144489 cites W2110065044 @default.
• W2548144489 cites W2112998845 @default.
• W2548144489 cites W2114883831 @default.
• W2548144489 cites W2115627587 @default.
• W2548144489 cites W2115707319 @default.
• W2548144489 cites W2117409731 @default.
• W2548144489 cites W2118453950 @default.
• W2548144489 cites W2126544407 @default.
• W2548144489 cites W2133255114 @default.
• W2548144489 cites W2144107414 @default.
• W2548144489 cites W2145254159 @default.
• W2548144489 cites W2145876349 @default.
• W2548144489 cites W2146119991 @default.
• W2548144489 cites W2155864063 @default.
• W2548144489 cites W2158413364 @default.
• W2548144489 cites W2165208382 @default.
• W2548144489 cites W2167763072 @default.
• W2548144489 cites W2168008759 @default.
• W2548144489 cites W2171224722 @default.
• W2548144489 cites W2179438025 @default.
• W2548144489 cites W2197292765 @default.
• W2548144489 cites W2208333084 @default.
• W2548144489 cites W2407993075 @default.
• W2548144489 cites W2506230487 @default.
• W2548144489 doi "https://doi.org/10.18632/oncotarget.13079" @default.
• W2548144489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5347763" @default.
• W2548144489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27825124" @default.
• W2548144489 hasPublicationYear "2016" @default.
• W2548144489 type Work @default.
• W2548144489 sameAs 2548144489 @default.
• W2548144489 citedByCount "65" @default.
• W2548144489 countsByYear W25481444892017 @default.
• W2548144489 countsByYear W25481444892018 @default.
• W2548144489 countsByYear W25481444892019 @default.
• W2548144489 countsByYear W25481444892020 @default.
• W2548144489 countsByYear W25481444892021 @default.
• W2548144489 countsByYear W25481444892022 @default.

• next